Abbott

Abbott

29,925.00
+100.00
(0.34%)
hide
Key Fundamentals
Add Ratio
Market Cap
63,376.00 Cr
EPS
665.62
PE Ratio
43.95
Dividend Yield
1.58 %
Industry
Healthcare
52 Week High
37,000.00
52 Week Low
25,325.00
PB Ratio
15.08
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
negative
ABB India shares have declined over 24% year-to-date and more than 35% over 12 months, underperforming peers Siemens and Cummins India. The stock currently trades at 57 times price-to-earnings ratio, representing a 23% discount to its five-year average of 74 times, while competitors trade at premiums to their historical averages. The decline stems from operational uncertainty, with sluggish customer decision-making delaying order conversions and JPMorgan expecting soft large-ticket business in the second half. Analysts believe the company has passed its margin peaks and revenues have been lower than anticipated due to macro factors. However, JPMorgan and Ambit Capital expect faster order conversion and stronger project pipeline ahead, with potential recovery in process industries capital expenditure supporting medium-term growth. Brokerages see 7% upside from current levels with 50% recommending a buy rating, though growth momentum is expected to remain range-bound.
neutral
Abbott India Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Darshan Gada as a Non-Executive Director. Gada was initially appointed as an Additional Director on August 18, 2025, based on the Nomination and Remuneration Committee's recommendation. The 43-year-old Chartered Accountant brings over 21 years of finance experience and currently serves as Regional Finance Director at Abbott Healthcare Private Limited. Remote e-voting will be conducted from September 15 to October 14, 2025, with results to be declared by October 16, 2025. The cut-off date for voting eligibility is September 5, 2025. KFin Technologies Limited will provide the e-voting facility, and the appointment requires ordinary resolution approval from shareholders.
positive
Abbott India has launched the FreeStyle Libre 2 Plus, a next-generation glucose monitoring device. The product provides continuous glucose readings every minute and includes optional alarm features for users.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,631.60
#1 3,96,634.10
34.59
#1 54,729.00
9.71
#1 10,980
-19.84
52.19
6,120.50
1,62,055.30
67.06
9,712.00
18.67
2,191
26.74
56.39
1,494.60
1,22,237.40
22.67
28,409.50
7.12
5,291
9.88
38.43
3,569.00
1,19,704.80
59.08
11,539.40
6.99
1,911
19.91
49.24
1,234.50
1,04,201.50
#1 18.34
33,741.20
16.73
5,725
1.26
39.35
2,454.90
1,02,393.00
53.53
12,744.20
#1 20.90
2,007
-18.14
39.95
985.95
99,405.90
21.46
23,511.00
18.55
4,615
2.60
42.63
1,905.60
87,916.10
23.93
22,909.50
13.74
3,306
#1 51.64
40.58
5,493.50
65,665.10
28.86
13,458.30
3.70
2,216
21.39
58.27
29,925.00
#10 63,376.00
#7 43.95
#10 6,684.70
#7 9.64
#10 1,414
#5 11.55
38.74

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
9.64 %
Net Income Growth
17.75 %
Cash Flow Change
-16.57 %
ROE
2.86 %
ROCE
-0.57 %
EBITDA Margin (Avg.)
5.63 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
2,337
2,665
2,960
3,416
3,792
4,208
4,391
4,997
5,503
6,097
6,685
6,871
Expenses
1,977
2,250
2,505
2,774
3,074
3,337
3,389
3,832
4,143
4,396
4,715
4,841
EBITDA
360
415
455
642
718
871
1,002
1,165
1,360
1,701
1,970
2,030
Operating Profit %
13 %
14 %
14 %
16 %
16 %
18 %
21 %
22 %
23 %
25 %
26 %
27 %
Depreciation
15
14
16
16
17
60
58
66
70
71
72
73
Interest
1
3
2
4
2
9
18
19
16
12
11
15
Profit Before Tax
344
398
437
622
699
803
926
1,080
1,274
1,618
1,887
1,943
Tax
115
143
160
220
249
210
235
281
324
417
473
486
Net Profit
229
255
277
401
450
593
691
799
949
1,201
1,414
1,452
EPS in ₹
107.75
120.12
130.19
188.81
211.93
279.04
325.04
375.87
446.80
565.28
665.62
683.40

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,374
1,617
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,194
5,917
Fixed Assets
96
109
110
81
105
270
251
271
237
225
336
Current Assets
1,226
1,451
1,893
2,266
2,761
3,205
3,519
3,853
3,025
3,246
4,742
Capital Work in Progress
4
3
6
2
1
2
1
1
4
10
18
Investments
0
0
0
0
0
0
0
0
0
0
0
Other Assets
1,274
1,505
1,950
2,333
2,835
3,275
3,589
3,953
4,315
4,958
5,563
Total Liabilities
1,374
1,617
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,194
5,917
Current Liabilities
397
382
632
668
857
891
1,031
1,203
1,206
1,343
1,407
Non Current Liabilities
39
39
47
55
75
224
207
201
161
152
277
Total Equity
938
1,196
1,387
1,693
2,009
2,432
2,602
2,820
3,189
3,699
4,233
Reserve & Surplus
916
1,174
1,366
1,672
1,987
2,410
2,581
2,799
3,167
3,678
4,212
Share Capital
21
21
21
21
21
21
21
21
21
21
21

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-30
91
62
-165
99
8
73
-86
107
52
269
Investing Activities
-187
-77
-155
-215
-257
-401
-72
-396
-148
-416
182
Operating Activities
215
249
307
153
499
626
727
948
893
1,213
1,012
Financing Activities
-58
-80
-90
-102
-143
-217
-582
-637
-639
-745
-925

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.18 %
0.18 %
0.18 %
0.16 %
0.16 %
0.16 %
0.16 %
DIIs
4.60 %
5.80 %
4.30 %
4.20 %
4.96 %
5.24 %
7.73 %
8.39 %
8.62 %
8.67 %
8.71 %
8.74 %
8.91 %
8.81 %
8.99 %
9.01 %
8.92 %
9.19 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.15 %
15.83 %
15.60 %
15.81 %
15.15 %
14.72 %
14.60 %
14.25 %
14.07 %
13.95 %
13.89 %
13.97 %
13.80 %
13.86 %
13.65 %
13.59 %
13.66 %
13.35 %
Others
4.26 %
3.38 %
5.11 %
5.01 %
4.91 %
5.06 %
2.68 %
2.37 %
2.32 %
2.39 %
2.42 %
2.13 %
2.12 %
2.16 %
2.21 %
2.25 %
2.28 %
2.31 %
No of Share Holders
0
84,478
75,540
73,417
83,236
90,567
82,113
83,526
72,086
69,582
68,885
72,252
69,382
71,588
69,449
67,892
69,934
67,584

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 40 55 65 250 275 275 325 410 475
Dividend Yield (%) 0.00 0.73 0.75 0.42 1.67 1.55 1.26 1.2 1.33 1.59

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 Jul 2021 DIVIDEND Dividend
₹ 155.00 /share
19 Jul 2021 16,224.75 17,427.95
21 Jul 2021 DIVIDEND Dividend
₹ 120.00 /share
19 Jul 2021 16,224.75 17,427.95
04 Aug 2022 DIVIDEND Dividend
₹ 130.00 /share
02 Aug 2022 16,529.20 20,621.45
04 Aug 2022 DIVIDEND Dividend
₹ 145.00 /share
02 Aug 2022 16,529.20 20,621.45
21 Jul 2023 DIVIDEND Dividend
₹ 145.00 /share
21 Jul 2023 20,970.55 23,665.10
21 Jul 2023 DIVIDEND Dividend
₹ 180.00 /share
21 Jul 2023 20,970.55 23,665.10
19 Jul 2024 DIVIDEND Dividend
₹ 410.00 /share
19 Jul 2024 25,945.60 28,795.65
08 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2024 25,945.60 28,136.85
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 28,526.15 29,115.20
05 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Feb 2025 26,518.15 26,142.55
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 30,145.75 30,348.45
25 Jul 2025 DIVIDEND Dividend
₹ 475.00 /share
25 Jul 2025 30,348.45 34,580.00
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 33,595.00 32,980.00
13 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
13 Aug 2025 30,348.45 32,342.10

Announcements

Announcement under Regulation 30 (LODR)-Change in Management6 hours ago
Announcement under Regulation 30 (LODR)-Change in ManagementSep 25, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 24, 2025
Closure of Trading WindowSep 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 12, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotSep 11, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2025
Unaudited Financial Results For The Quarter Ended June 30 2025.Aug 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended On June 30 2025.Aug 04, 2025
Disclosure Under Regulation 30Aug 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 29, 2025
Communication Providing The Weblink Including Path Of Annual Report.Jul 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 18, 2025
Notice Of The 81St Annual General Meeting Of The Company.Jul 18, 2025
Reg. 34 (1) Annual Report.Jul 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Closure of Trading WindowJun 26, 2025
Communication To Shareholders : Intimation About Tax Deduction At Source On Dividend.Jun 18, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Record Date For Entitlement Of DividendMay 15, 2025
Annual General Meeting On August 13 2025May 15, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 15, 2025
Results For The Financial Year Ended March 31 2025May 15, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 07, 2025
Board Meeting Intimation for Intimation Under Regulation 29 (1) (A) And (E) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.May 07, 2025
Announcement Under Regulation 30.Apr 30, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 26, 2025
Closure of Trading WindowMar 25, 2025
Rumour verification - Regulation 30(11)Mar 06, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 27, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 20, 2025
Integrated Filing (Financial)Feb 06, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 05, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Board Meeting Intimation for Intimation Of Board Meeting Scheduled On February 5 2025 For Considering Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024.Jan 28, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-274878
-2.60%
-2.84%
Axis Midcap Direct Plan-Growth
0.00%
-166043
-1.68%
-1.82%
Canara Robeco Large and Mid Cap Fund Direct-Growth
0.00%
-144836
-1.79%
-1.95%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-87483
-0.60%
-0.66%
SBI Innovative Opportunities Fund Direct-Growth
0.00%
-86045
-3.74%
-4.02%
SBI MNC Direct Plan-Growth
0.00%
-80000
-4.20%
-4.44%
PGIM India Midcap Fund Direct-Growth
0.00%
-74300
-2.05%
-2.23%
Nippon India Pharma Fund Direct-Growth
0.00%
-68677
-2.59%
-2.70%
Franklin India Mid Cap Fund Direct-Growth
0.00%
-52304
-1.34%
-1.44%
HSBC Midcap Fund Direct-Growth
0.00%
-40168
-1.08%
-1.69%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-36000
-2.86%
-3.08%
SBI Dividend Yield Fund Direct - Growth
0.00%
-35000
-1.23%
-1.33%
Canara Robeco Flexi Cap Fund Direct-Growth
0.00%
-32022
-0.76%
-0.82%
Canara Robeco Large Cap Fund Direct-Growth
0.00%
-31701
-0.61%
-0.66%
SBI Quant Fund Direct-Growth
0.00%
-19856
-1.74%
-1.66%
SBI Retirement Benefit Fund - Aggressive Plan Direct - Growth
0.00%
-19700
-2.10%
-2.29%
Edelweiss Balanced Advantage Fund Direct-Growth
0.00%
-17911
-0.44%
-0.48%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.00%
-17413
-1.53%
-1.66%
Canara Robeco Mid Cap Fund Direct - Growth
0.00%
-16693
-1.65%
-1.83%
LIC MF Large & Mid Cap Fund Direct-Growth
0.00%
-15806
-1.65%
-1.75%
Mahindra Manulife Mid Cap Fund Direct - Growth
0.00%
-14000
-1.13%
-1.23%
Baroda BNP Paribas Midcap Fund Direct-Growth
0.00%
-14000
-2.04%
-2.21%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
0.00%
-12933
-4.82%
-5.10%
Aditya Birla Sun Life MNC Fund Direct-Growth
0.00%
-10233
-0.87%
-0.94%
360 ONE FlexiCap Fund Direct - Growth
0.00%
-10216
-1.63%
-0.99%

Technical Indicators

RSI(14)
Neutral
36.86
ATR(14)
Less Volatile
663.68
STOCH(9,6)
Neutral
41.03
STOCH RSI(14)
Overbought
87.78
MACD(12,26)
Bullish
38.40
ADX(14)
Strong Trend
38.06
UO(9)
Bearish
36.89
ROC(12)
Downtrend And Accelerating
-3.45
WillR(14)
Neutral
-66.67

About Abbott

Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Chairperson NameMunir Shaikh